Biocytogen Shareholders Approve New Non-Executive Director at 2026 EGM

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) just unveiled an update.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. reported the poll results of its first extraordinary general meeting of 2026, held in a hybrid physical and virtual format in Beijing on February 12, with shareholders representing 59.1% of voting shares in attendance. The company confirmed that meeting procedures complied with PRC law and its articles, and that the poll process was independently scrutinized and deemed lawful and valid.

Shareholders overwhelmingly approved the appointment of Liu Hongkang as a non-executive director, with more than 99.99% of votes cast in favor and negligible opposition or abstentions. Liu’s appointment, effective immediately and running through the current board’s second session term, slightly reshapes board composition and signals continued focus on strengthening corporate governance and oversight for investors.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong under stock code 2315. The company operates in the biotechnology and pharmaceutical sector, focusing on drug discovery and development, and is governed by a board comprising executive, non-executive and independent non-executive directors in line with Hong Kong listing rules.

Average Trading Volume: 1,855,918

Technical Sentiment Signal: Buy

Current Market Cap: HK$20.34B

For detailed information about 2315 stock, go to TipRanks’ Stock Analysis page.